The Europe Ruminant Vaccines Market would witness market growth of 6.3% CAGR during the forecast period (2024-2031).
The Germany market dominated the Europe Ruminant Vaccines Market by Country in 2023, and would continue to be a dominant market till 2031; thereby, achieving a market value of $331.1 million by 2031. The UK market is exhibiting a CAGR of 5.3% during (2024 - 2031). Additionally, The France market would experience a CAGR of 7.1% during (2024 - 2031).
Vaccines targeting respiratory pathogens such as Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Bovine Respiratory Syncytial Virus (BRSV) are used to prevent diseases like bovine respiratory disease complex (BRDC), contagious caprine pleuropneumonia (CCPP), and ovine pulmonary adenocarcinoma (OPA). Vaccination helps reduce the incidence and severity of respiratory infections, decrease antibiotic usage, and improve animal welfare.
Similarly, reproductive disorders can have significant economic implications for ruminant producers due to reduced fertility, abortions, and neonatal mortality. Vaccines targeting reproductive pathogens such as Brucella abortus, Chlamydia spp., and bovine herpesvirus 1 (BHV-1) are used to prevent diseases like brucellosis, campylobacteriosis, and infectious bovine rhinotracheitis (IBR). Vaccination helps maintain herd fertility, reduce reproductive losses, and prevent the spread of sexually transmitted infections among breeding animals.
Europe is a major meat producer, including beef, veal, lamb, and mutton. As per Eurostat, at the end of 2022, there were 134 million pigs, 75 million bovine animals, and 70 million sheep and goats in the EU. The EU produced a provisional 6.6 million tons of bovine meat (beef and veal carcasses) by 2022. About 70 % of the EU’s veal meat was produced in three countries, the Netherlands (26.9 %), Spain (22.9 %), and France (18.9 %). In conclusion, the region’s high meat production promotes the market’s growth.
Based on Animal Type, the market is segmented into Cattle, and Sheep & Goats. Based on Vaccines Type, the market is segmented into Modified/ Attenuated Live, Inactivated (Killed), and Others. Based on Route of Administration, the market is segmented into Injectable, and Intranasal. Based on Indication, the market is segmented into Bovine Respiratory Diseases (BRD), Diarrhea/ Scours, FMD, Clostridial Diseases, Leptospirosis, BVD Infection, and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The Germany market dominated the Europe Ruminant Vaccines Market by Country in 2023, and would continue to be a dominant market till 2031; thereby, achieving a market value of $331.1 million by 2031. The UK market is exhibiting a CAGR of 5.3% during (2024 - 2031). Additionally, The France market would experience a CAGR of 7.1% during (2024 - 2031).
Vaccines targeting respiratory pathogens such as Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Bovine Respiratory Syncytial Virus (BRSV) are used to prevent diseases like bovine respiratory disease complex (BRDC), contagious caprine pleuropneumonia (CCPP), and ovine pulmonary adenocarcinoma (OPA). Vaccination helps reduce the incidence and severity of respiratory infections, decrease antibiotic usage, and improve animal welfare.
Similarly, reproductive disorders can have significant economic implications for ruminant producers due to reduced fertility, abortions, and neonatal mortality. Vaccines targeting reproductive pathogens such as Brucella abortus, Chlamydia spp., and bovine herpesvirus 1 (BHV-1) are used to prevent diseases like brucellosis, campylobacteriosis, and infectious bovine rhinotracheitis (IBR). Vaccination helps maintain herd fertility, reduce reproductive losses, and prevent the spread of sexually transmitted infections among breeding animals.
Europe is a major meat producer, including beef, veal, lamb, and mutton. As per Eurostat, at the end of 2022, there were 134 million pigs, 75 million bovine animals, and 70 million sheep and goats in the EU. The EU produced a provisional 6.6 million tons of bovine meat (beef and veal carcasses) by 2022. About 70 % of the EU’s veal meat was produced in three countries, the Netherlands (26.9 %), Spain (22.9 %), and France (18.9 %). In conclusion, the region’s high meat production promotes the market’s growth.
Based on Animal Type, the market is segmented into Cattle, and Sheep & Goats. Based on Vaccines Type, the market is segmented into Modified/ Attenuated Live, Inactivated (Killed), and Others. Based on Route of Administration, the market is segmented into Injectable, and Intranasal. Based on Indication, the market is segmented into Bovine Respiratory Diseases (BRD), Diarrhea/ Scours, FMD, Clostridial Diseases, Leptospirosis, BVD Infection, and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
List of Key Companies Profiled
- Boehringer Ingelheim International GmbH
- Zoetis, Inc.
- Merck & Co., Inc.
- Bimeda, Inc.
- Elanco Animal Health, Inc.
- Virbac
- Ceva Sante Animale
- CZ Vaccines S.A.U. (Zendal Health S.A.)
- Indian Immunologicals Ltd. (National Dairy Development Board)
- Vaxxinova International BV (EW Group)
Market Report Segmentation
By Animal Type- Cattle
- Sheep & Goats
- Modified/ Attenuated Live
- Inactivated (Killed)
- Others
- Injectable
- Intranasal
- Bovine Respiratory Diseases (BRD)
- Diarrhea/ Scours
- FMD
- Clostridial Diseases
- Leptospirosis
- BVD Infection
- Others
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 5. Europe Ruminant Vaccines Market by Animal Type
Chapter 6. Europe Ruminant Vaccines Market by Vaccines Type
Chapter 7. Europe Ruminant Vaccines Market by Route of Administration
Chapter 8. Europe Ruminant Vaccines Market by Indication
Chapter 9. Europe Ruminant Vaccines Market by Country
Chapter 10. Company Profiles
Companies Mentioned
- Boehringer Ingelheim International GmbH
- Zoetis, Inc.
- Merck & Co., Inc.
- Bimeda, Inc.
- Elanco Animal Health, Inc.
- Virbac
- Ceva Sante Animale
- CZ Vaccines S.A.U. (Zendal Health S.A.)
- Indian Immunologicals Ltd. (National Dairy Development Board)
- Vaxxinova International BV (EW Group)
Methodology
LOADING...